WallStreetZenWallStreetZen

NASDAQ: EVO
Evotec Se Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their EVO stock forecasts and price targets.

Forecast return on equity

Is EVO forecast to generate an efficient return?

Company
10.28%
Industry
30.74%
Market
90.47%
EVO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EVO forecast to generate an efficient return on assets?

Company
4.82%
Industry
15.4%
EVO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EVO earnings per share forecast

What is EVO's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.43
Avg 2 year Forecast
-$0.21
Avg 3 year Forecast
$0.44

EVO revenue forecast

What is EVO's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$964.7M
Avg 2 year Forecast
$1.1B
Avg 3 year Forecast
$1.2B

EVO vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
EVO$4.27N/AN/A
ANIP$62.56$82.00+31.07%Strong Buy
INDV$13.89$13.00-6.41%Strong Buy
SUPN$32.03$36.00+12.39%Hold
DVAX$10.27$26.25+155.60%Hold
View Top Pharmaceutical Stocks

Evotec Se Stock Forecast FAQ

What is EVO's earnings growth forecast for 2025-2027?

(NASDAQ: EVO) Evotec Se's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 25.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Evotec Se's earnings in 2025 is N/A.On average, 2 Wall Street analysts forecast EVO's earnings for 2025 to be -$75,460,219, with the lowest EVO earnings forecast at -$110,083,143, and the highest EVO earnings forecast at -$40,837,295. On average, 2 Wall Street analysts forecast EVO's earnings for 2026 to be -$37,286,226, with the lowest EVO earnings forecast at -$78,123,521, and the highest EVO earnings forecast at $3,551,069.

In 2027, EVO is forecast to generate $78,123,521 in earnings, with the lowest earnings forecast at $78,123,521 and the highest earnings forecast at $78,123,521.

If you're new to stock investing, here's how to buy Evotec Se stock.

What is EVO's revenue growth forecast for 2025-2027?

(NASDAQ: EVO) Evotec Se's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Evotec Se's revenue in 2025 is N/A.On average, 1 Wall Street analysts forecast EVO's revenue for 2025 to be $171,287,594,538, with the lowest EVO revenue forecast at $171,287,594,538, and the highest EVO revenue forecast at $171,287,594,538. On average, 1 Wall Street analysts forecast EVO's revenue for 2026 to be $193,744,555,653, with the lowest EVO revenue forecast at $193,744,555,653, and the highest EVO revenue forecast at $193,744,555,653.

In 2027, EVO is forecast to generate $213,220,394,241 in revenue, with the lowest revenue forecast at $213,220,394,241 and the highest revenue forecast at $213,220,394,241.

What is EVO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: EVO) forecast ROA is 4.82%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 15.4%.

What is EVO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: EVO) Evotec Se's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that EVO's EPS will be -$0.43 for 2025, with the lowest EPS forecast at -$0.62, and the highest EPS forecast at -$0.23. On average, analysts forecast that EVO's EPS will be -$0.21 for 2026, with the lowest EPS forecast at -$0.44, and the highest EPS forecast at $0.02. In 2027, EVO's EPS is forecast to hit $0.44 (min: $0.44, max: $0.44).

What is EVO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: EVO) forecast ROE is 10.28%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.